Litcius/Paper detail

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H. O’Donnell, Jonathan E. Rosenberg, Daniel M. Geynisman, Daniel P. Petrylak, Jean Hoffman‐Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S. van der Heijden, Cora N. Sternberg, Nicole N. Davarpanah, Thomas Powles

2021The Lancet Oncology412 citationsDOIOpen Access PDF

Topics & Concepts

AtezolizumabAdjuvantMedicineUrothelial carcinomaOncologyOpen labelCarcinomaInternal medicineUrologyRandomized controlled trialCancerImmunotherapyBladder cancerPembrolizumabBladder and Urothelial Cancer TreatmentsEsophageal Cancer Research and TreatmentUrinary and Genital Oncology Studies
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial | Litcius